Revenue: As of FY2025 Q1, the actual value is USD 10.26 K.EPS: As of FY2025 Q1, the actual value is USD -0.33.<h3>Segment Revenue</h3><ul><li>Integra Segment: Revenue for the three months ended March 31, 2025 was $10,258.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): For the three months ended March 31, 2025, Integra reported a net loss of - $298,401, Scienture reported a net loss of - $1,420,095, and Unallocated reported a net loss of - $1,345,501, totaling a net loss of - $3,063,997.</li><li>Interest Expense: Scienture incurred $77,500 in interest expense, while Unallocated incurred $593,284, totaling $670,784 for the three months ended March 31, 2025.</li><li>Depreciation: Depreciation expense for the three months ended March 31, 2025 was $500.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities from continuing operations for the three months ended March 31, 2025 was - $2,956,457.</li><li>Investing Cash Flow: No cash was used in investing activities for the three months ended March 31, 2025.</li><li>Financing Cash Flow: Net cash provided by financing activities from continuing operations for the three months ended March 31, 2025 was $4,697,999.</li></ul><h3>Unique Metrics</h3><ul><li>Research and Development Expenses: Total research and development expenses for the three months ended March 31, 2025 were $574,679, with specific allocations to projects SCN-102, SCN-104, SCN-106, and SCN-107.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to use proceeds from divestitures to facilitate high-growth commercial and strategic product development activities at its Scienture, LLC subsidiary.</li><li>Non-Core Business: The company entered into agreements to sell its membership interests in IPS and Bonum Health, Inc. to Tollo Health, Inc., with the transaction expected to close on June 30, 2025.</li></ul>

Scienture | 10-Q: FY2025 Q1 Revenue: USD 10.26 K